PI3K: A potential therapeutic target for cancer
Description
<jats:title>Abstract</jats:title><jats:p>Phosphatidylinositol 3‐kinase (PI3K), one member of lipid kinase family, has been demonstrated to play a key role in regulating cell proliferation, adhesion, survival, and motility. Recent studies indicate that PI3K related signaling pathway is one of the most commonly activated pathways in human cancers. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, Inhibitors targeting PI3K or nodes in this pathway, AKT and mTOR, are best studied and have reached clinical trials. In this review, we will focus on recent progress on understanding of PI3Ks signaling pathway and the development of PI3K inhibitors. J. Cell. Physiol. 227: 2818–2821, 2012. © 2011 Wiley Periodicals, Inc.</jats:p>
Journal
-
- Journal of Cellular Physiology
-
Journal of Cellular Physiology 227 (7), 2818-2821, 2012-03-20
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1364233268247783808
-
- ISSN
- 10974652
- 00219541
-
- Data Source
-
- Crossref